ProPhase Labs, Inc. (NASDAQ:PRPH) Q1 2023 Results Conference Call May 11, 2023 11:00 AM ET

Company Participants

Ted Karkus - CEO and Chairman

Conference Call Participants

Hunter Diamond - Diamond Equity Research

Yi Chen - H.C. Wainwright

Operator

Good day, and welcome to the ProPhase Labs Inc. First Quarter 2023 Financial Results and Corporate Update Conference Call. All participants will be in listen only mode [Operator Instructions]. Please note this event is being recorded.

I would now like to turn the conference over to Ted Karkus, CEO and Chairman of the Board of ProPhase Labs. Please go ahead.

Ted Karkus

Thank you, Sarah. And thank you everybody for joining me today. Before we get started, I would like to remind you of the company’s Safe Harbor language. During this presentation, we will make forward-looking statements, including statements regarding our strategies, plans, objectives and initiatives and the underlying assumptions. While we believe that these forward-looking statements are reasonable as and when made, forward-looking statements are based on expectations that involve risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, our ability to obtain and maintain necessary regulatory approval, general economic conditions, consumer demand for our products and services, challenges relating to entering into and growing new business lines, the competitive environment and the risk factors listed from time-to-time in our filings with the SEC filings. This call will present non-GAAP financial measures, such as adjusted EBITDA. Reconciliation of these non-GAAP measures to the most comparable GAAP measures are included in the earnings release furnished to the SEC prior to this call and available on our Web site.

All right, now that we’ve got the forward looking statements out of the way, I want to welcome you all and really appreciate you joining me and appreciate your interest in our company ProPhase Labs. Just couple of quick shoutouts. First of all, we work with a company called Renmark that creates virtual non-deal roadshows. I do these approximately twice per month. If you are interested in hearing updates on our company, our company is constantly evolving. We are a dynamic company. We are growing in so many different areas. We are working on so many exciting things. There is so much going on. And so I like to keep our shareholders up-to-date. And if you are interested in keeping up to date, please contact Renmark, find out -- sign up with them, find out when we have another VNDR. And feel free those are video calls and I go through slide presentations and so forth. I should also remind everyone that, we have presentations on our Web site. We have two presentations. One is just for biotech division and the other is our company presentation, that was significantly updated recently. So if you haven't looked at it, you might want to go through our company presentation update, I think just in the last couple of weeks. So go to our Web site, it is really a wealth of information. I also want to just highlight, we are now covered by four companies ThinkEquity, H.C. Wainwright, Joshua Levine, Confluence, and our most recent Diamond Equity Research. All four of these analysts that are following our company have us estimated to lose money this year, while having stock price objectives of roughly $15 to $20 per share. The most recent we updated research report from Diamond Equity has us with a $20 dollars stock price objective.